Roth Capital Downgrades CorMedix (CRMD) to Neutral
Tweet
Share
E-mailGet Alerts CRMD Hot Sheet
Price: $8.38 +1.45%
Rating Summary:
10 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Rating Summary:
10 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Join SI Premium – FREE
Roth Capital downgraded CorMedix (NYSE: CRMD) from Buy to Neutral with a price target of $7.50 (from $2.50).
For an analyst ratings summary and ratings history on CorMedix click here. For more ratings news on CorMedix click here.
Shares of CorMedix closed at $7.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kepler Cheuvreux Upgrades Entain PLC (ENT:LN) (GMVHF) to Buy
- Vibra Energia SA (VBBR3:BZ) PT Raised to R$43 at JPMorgan
- BofA Securities Downgrades Edison International (EIX) to Neutral, 'A once-in-a-generation reform opportunity falls short'
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
